AEterna Zentaris Inc. (USA) (AEZS) Up Big Again Following Pivotal Phase 3 Gets Under Way


Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) are having yet another extraordinary day after gains of over 100% yesterday. The rally, which was spurred on by the announcement that the company’s phase 3 study for their drug Macrilen, a treatment specific to those suffering from growth harmone deficiencies, has continued again this morning.

In additional news from the company, they’ve announced that 11,000 Series B Common Share Purchase Warrants have been exercised, equating to 365,518 common shares entering the market.The stock is up 56.90% or $4.85 after the positive news, hitting $13.37 per share. About 11.73 million shares traded hands or 2105.98% up from the average. AEZS has risen 1320.00% since April 22, 2015 and is uptrending. It has outperformed by 1321.01% the S&P500.

Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $11 is the highest target while $1 is the lowest. The $6 average target is -55.12% below today’s ($13.37) stock price. Aeterna Zentaris Inc. was the topic in 3 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Maxim Group maintained the stock on November 23 with “Buy” rating.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical firm engaged in developing treatments in oncology, endocrinology and women’s health. The company has a market cap of $41.84 million. The Firm has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. It currently has negative earnings. The Company’s drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds , which are in pre-clinical development.